We're buying more of this life sciences stock after an earnings-driven decline

We're buying 30 shares of Danaher at roughly $199 each. Following Tuesday's trade, Jim Cramer's Charitable Trust will own 550 shares of DHR, increasing its weighting in the portfolio to 4.08% from 3.87%. Danaher reported a better-than-expected third-quarter Tuesday morning, but the stock is under pressure in early trading due to uncertainty around the recovery in its bioprocessing business. For the quarter, Danaher revenues fell 10.5% to $6.87 billion, beating estimates of $6.

Danaher pointed out that its bioprocessing orders were down in the third quarter versus the second quarter and were expected to decline again in the fourth. We pay close attention to orders because they precede sales. Danaher's view that orders will decline over the next two quarters contrasts the upbeat data point its bioprocessing peer Sartorious said last week.

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

US Stock Market's Stellar 2023 Run Under Threat as Bond Vigilantes Make a ComebackStocks Analysis by James Picerno covering: Vanguard Total Stock Market Index Fund ETF Shares, LPL Financial Holdings Inc, United States 10-Year, SPDR® Bloomberg High Yield Bond ETF. Read James Picerno's latest article on Investing.com
Fonte: Investingcom - 🏆 450. / 53 Consulte Mais informação »

The stock market may be ignoring this 'bad news' as earnings get under way‘Stealth stagnation’ has gone under the radar, says BlackRock team
Fonte: MarketWatch - 🏆 3. / 97 Consulte Mais informação »